These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 21766440)

  • 61. Ethnic differences in drug utilization pattern during pregnancy: a cross-sectional study.
    Baraka MA; Steurbaut S; Coomans D; Dupont AG
    J Matern Fetal Neonatal Med; 2013 Jun; 26(9):900-7. PubMed ID: 23350574
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Safety and efficacy of drugs in pregnancy.
    Knoppert D
    J Popul Ther Clin Pharmacol; 2011; 18(3):e506-12. PubMed ID: 22113261
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Teratogenic mechanisms associated with prenatal medication exposure.
    van Gelder MM; van Rooij IA; de Jong-van den Berg LT; Roeleveld N
    Therapie; 2014; 69(1):13-24. PubMed ID: 24698184
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Association between change of health care providers and pregnancy exposure to FDA category C, D and X drugs.
    Yang J; Xie R; Krewski D; Wang Y; Walker M; Cao W; Wen SW
    Chin Med J (Engl); 2014; 127(4):702-6. PubMed ID: 24534226
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Medication Safety During Pregnancy: Improving Evidence-Based Practice.
    Sinclair SM; Miller RK; Chambers C; Cooper EM
    J Midwifery Womens Health; 2016; 61(1):52-67. PubMed ID: 26771055
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Risk Management of Teratogenic Drugs ~The Current States of Practice in Europe, US and Japan~].
    Takagi T; van Bennekom C; Amann S; Hattori C; Shirakuni Y; Sato T; Nasu M
    Yakugaku Zasshi; 2015; 135(10):1161-8. PubMed ID: 26234426
    [TBL] [Abstract][Full Text] [Related]  

  • 67. FDA labeling system for drugs in pregnancy.
    Boothby LA; Doering PL
    Ann Pharmacother; 2001 Nov; 35(11):1485-9. PubMed ID: 11724104
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Teratogenic drugs and their drug interactions with hormonal contraceptives.
    Ahn MR; Li L; Shon J; Bashaw ED; Kim MJ
    Clin Pharmacol Ther; 2016 Sep; 100(3):217-9. PubMed ID: 27090193
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The drug development process and the pregnant woman.
    Frederiksen MC
    J Midwifery Womens Health; 2002; 47(6):422-5. PubMed ID: 12484663
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Assessment of foetal risk associated with 93 non-US-FDA approved medications during pregnancy.
    Al-Jedai AH; Balhareth SS; Algain RA
    Saudi Pharm J; 2012 Oct; 20(4):287-99. PubMed ID: 23960803
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Risk perception regarding drug use in pregnancy.
    Widnes SF; Schjøtt J
    Am J Obstet Gynecol; 2017 Apr; 216(4):375-378. PubMed ID: 27988271
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The Pregnancy Registry program at Glaxo Wellcome Company.
    White AD; Andrews EB
    J Allergy Clin Immunol; 1999 Feb; 103(2 Pt 2):S362-3. PubMed ID: 9949340
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Drug use by pregnant women in six Brazilian cities].
    Mengue SS; Schenkel EP; Duncan BB; Schmidt MI
    Rev Saude Publica; 2001 Oct; 35(5):415-20. PubMed ID: 11723511
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Classification of drugs for teratogenic risk.
    Alván G; Danielsson BR; Kihlström I; Lundborg P; Prame B; Ridley E; Sannerstedt R
    Eur J Clin Pharmacol; 1995; 48(3-4):177-8. PubMed ID: 7589037
    [No Abstract]   [Full Text] [Related]  

  • 75. Performing research in pregnancy: Challenges and perspectives.
    Hartman RI; Kimball AB
    Clin Dermatol; 2016; 34(3):410-5. PubMed ID: 27265080
    [TBL] [Abstract][Full Text] [Related]  

  • 76. An overview of upcoming changes in pregnancy and lactation labeling information.
    Mosley JF; Smith LL; Dezan MD
    Pharm Pract (Granada); 2015; 13(2):605. PubMed ID: 26131048
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Triptans are not teratogenic].
    Med Monatsschr Pharm; 2015 Mar; 38(3):110-1; discussion 111. PubMed ID: 26364399
    [No Abstract]   [Full Text] [Related]  

  • 78. Drug use in pregnancy; a point to ponder!
    Sachdeva P; Patel BG; Patel BK
    Indian J Pharm Sci; 2009 Jan; 71(1):1-7. PubMed ID: 20177448
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Defining a medication class as a teratogen: may the evidence be with you and not the FDA Pregnancy Risk Categories.
    Kaplan YC; Karadaş B; Kaya-Temiz T
    Acad Emerg Med; 2015 Jun; 22(6):769. PubMed ID: 25999059
    [No Abstract]   [Full Text] [Related]  

  • 80. [An update in drug use during pregnancy: risk classification].
    Gallego Úbeda M; Delgado Téllez de Cepeda L; Campos Fernández de Sevilla Mde L; De Lorenzo Pinto A; Tutau Gómez F
    Farm Hosp; 2014 Jul; 38(4):364-78. PubMed ID: 25137169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.